Hims & Hers Health will report its second-quarter 2026 earnings tonight at 5:00 p.m. ET, with the company facing heightened investor scrutiny following a Federal Trade Commission lawsuit filed on July 29 alleging unlawful sharing of consumers’ health data with Meta and Snap, along with deceptive billing practices.
The FTC, joined by Utah and California, filed a complaint in federal court accusing Hims of sharing sensitive health information with third-party advertising platforms despite promising to protect patient privacy. According to the FTC’s complaint, Hims automatically shared certain consumer actions on its website with Meta and Snap through tracking technologies, and also shared lists of customers with those platforms. The agency also alleges that Hims misled consumers by charging them for prescriptions almost immediately after intake form submission, despite assurances they would consult with a medical provider before being charged.
The FTC further alleged that Hims made it difficult for consumers to cancel subscriptions—prior to 2023, the company only allowed cancellations via phone, email, or chat, and even after introducing online cancellation, the company hid the cancellation button from consumers, requiring them to navigate several steps before seeing the word “cancel.” The investigation spanned nearly three years, according to Hims’ own response statement issued July 29.
Hims stock fell sharply on the lawsuit announcement, dropping between 10% and 15% on July 29, according to reports from CNBC and Reuters. However, the stock has since recovered, rallying 11% to 29% by early August, with shares closing at $31.59 on Friday, August 9, according to stock analysis sites. Analyst sentiment remains cautious—the consensus rating across Wall Street is “Hold,” with Morningstar setting a $23 fair value target, and the average 12-month price target at $29.23, below the current trading level.
For Q2 2026, Hims provided guidance in May expecting revenue between $680 million and $700 million, with adjusted EBITDA of $35 million to $55 million. Analyst consensus, per social media research, anticipates revenue of $690 million to $700 million and an EPS loss of $0.05 to $0.10. Options traders are bracing for volatility, with data compiled by Bloomberg suggesting the stock could move as much as 14% following the earnings release.
Hims has denied wrongdoing in response to the FTC lawsuit, stating that the complaint “disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and mischaracterizes our business practices.” The company emphasized on social media that it will defend itself vigorously in court. The case will be decided by the U.S. District Court for the Northern District of California.
Sources
- Federal Trade Commission — FTC press release and complaint details on Hims lawsuit, filed July 29, 2026
- Hims Investor Relations — official announcement of Q2 2026 earnings call on August 10, 2026 at 5:00 p.m. ET
- CNBC — reporting on stock decline and FTC lawsuit on July 29, 2026
- Reuters — stock price movement and lawsuit details, July 29, 2026
- MarketBeat — Q2 2026 earnings preview and stock recovery reporting, August 5, 2026
- Morningstar — analyst commentary on FTC lawsuit as “new legal overhang” and $23 fair value target
- TikR — reporting on stock recovery following FTC lawsuit, August 4, 2026
- Small Cap Movers — stock decline of 14.75% on July 29, 2026
- Stock Analysis — consensus analyst rating and 12-month price target data
